Selinexor monotherapy induced deep and durable responses in the phase IIb SADAL study of patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) who are not candidates for autologous stem cell transplantation (ASCT). Responses were observed across both the germinal center B-cell (GCB) and non-GCB subtypes of the disease.
The overall response rate (ORR) in patients enrolled in SADAL (Selinexor Against Diffuse Aggressive Lymphoma) was 29.6%, with a complete response (CR) rate of 9.6%. The response rates were 34.0% in patients with the GCB subtype and 21.1% in those with the non-GCB subtype, reported Marie Maerevoet, MD, at the 2018 American Society of Hematology meeting.1
Median overall survival was 9.1 months in the overall intent-to-treat (mITT) group, improving to 29.7 months in patients who achieved a CR or partial response (PR).
... to read the full story